Annual report [Section 13 and 15(d), not S-K Item 405]

Net Loss Per Share

v3.26.1
Net Loss Per Share
12 Months Ended
Dec. 31, 2025
Net Income (Loss) Per Share [Abstract]  
Net Loss Per Share

14. Net Loss Per Share

 

The Company computes net income (loss) per share using the two-class method. The two-class method uses an earnings allocation formula that determines net income (loss) per share for common stock and any participating securities according to dividends declared and participation rights in undistributed earnings.

  

Diluted net income (loss) per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include: (i) outstanding stock options and restricted stock units; (ii) common stock to be issued upon the assumed exercise of the Company’s common stock warrants; (iii) convertible preferred stock; and (iv) prior to issuance, the issuable warrants related to the Company’s March 2023 private placement financing.

 

The following table sets forth the computation of basic and diluted net loss per share of common and preferred stock (in thousands, except share and per share data):

 

    Year Ended
December 31,
    Year Ended
December 31,
 
    2024     2025  
Basic net loss per share            
Numerator:            
Net loss   $ (36,729 )   $ (26,555 )
Cash Dividends to Series B holders     (1,095 )    
-
 
Net loss attributable to common shares, basic and diluted     (37,824 )     (26,555 )
                 
Denominator:                
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted     6,698,513       15,886,876  
Net loss per share attributable to common stockholders, basic and diluted   $ (5.65 )   $ (1.67 )

 

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:

 

    Year Ended
December 31,
    Year Ended
December 31
 
    2024     2025  
             
Options to purchase common stock     1,367,114       2,033,114  
Warrants to purchase common stock     478,419       478,419  
Restricted stock units     2,177       3,677  
Common stock issuable upon conversion of Series B-2 convertible preferred stock     300,000      
-
 
Common stock issuable upon conversion of Series A-2 Prime convertible preferred stock     1,255,145       462,245  
Warrants to purchase convertible preferred stock     16,095,817       15,818,817  
Total     19,498,672       18,796,272